ANG Lifesciences India has executed an Asset purchase deal with Ind-Swift for acquisition of two formulation manufacturing facilities for Rs 60 crore. payable through internal accrual & bank funding on deferred payment basis up to June 30, 2024, located at Baddi (HP). The plants are now running as Unit 5 & Unit 6 of ANG Lifesciences India respectively. The said acquisition has helped in scaling up ANG’s manufacturing capacity to meet the growing demand from the domestic as well as international markets.
This acquisition is in line with ANG’s long-term strategic objective to become a complete Healthcare Solution Provider aimed at creating a broad-based basket of Pharmaceutical Formulation Products for a differentiated and comprehensive profile in pharmaceutical markets.
ANG Lifesciences India, incorporated in the year 2006, started with the business of manufacturing and marketing of finished pharmaceutical formulation in a dosage form of Sterile Dry Powder Injection Vial.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: